Landmark BioVentures launches spin-off biotech to tackle fibrotic, neoplastic and neovascularised conditions
May 20, 2025Research and Development Aix-Marseille University, Cardiology, Corporate, Landmark BioVentures, Massalia Therapeutics, Oncology, cardiovascular research, oncology
Landmark BioVentures and researchers at Aix-Marseille University in Marseille, France, have launched Massalia Therapeutics. Marking Landmark’s seventh company, the spin-off …
Duck Creek Technologies appoints Tyler Jones as chief marketing officer
May 20, 2025Business Services, Pharmaceutical Consultancy Services Corporate, Duck Creek Technologies, appointment, chief marketing officer, property and casualty (P&C) insurance
Duck Creek Technologies has appointed Tyler Jones as its new chief marketing officer (CMO). He will lead the company’s global …
FDA approves diagnostic tool for MET-targeted lung cancer therapy
May 19, 2025Research and Development FDA, Oncology, Roche, lung cancer, non-squamous non-small cell lung cancer
The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay as a diagnostic tool to …
Cold plasma therapy shown to be 100% effective against pneumonia-causing bacteria
May 19, 2025Research and Development Infections and infestations, MRSA, Viromed Medical, intensive care, lung therapy, ventilator-associated pneumonia (VAP)
A breakthrough in lung therapy has been reported by German biotech company Viromed Medical whose cold plasma treatment has demonstrated …
Medable unveils oncology trial platform aimed at reducing logistical hurdles
May 16, 2025Biotech/start-up, Business Services, Research and Development, Sales and Marketing, Technical Consultancy AI, FDA, Medable, Oncology, digital platform, oncology research, oncology trials
Clinical trial technology provider, Medable, has launched a digital platform designed to support oncology clinical trials by addressing growing operational …
Moleculin secures EMA approval to expand acute myeloid leukaemia trial across EU
May 16, 2025Research and Development Clinical Trial Application (CTA), European Union (EU), FDA, Food and Drug Administration, Moleculin Biotech, Oncology, Orphan Drug Designation (ODD), acute myeloid leukaemia
Moleculin Biotech has received approval from the European Medicines Agency (EMA) to expand its phase 3 ‘MIRACLE’ trial into nine …
Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome
May 15, 2025Research and Development Guillain-Barré Syndrome (GBS), Hansa Biopharma, Immunology, Peripheral Nerve Society (PNS) Annual Meeting, Rare Diseases
Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …
Neogap Therapeutics selected to join EIC Soft-landing Programme, supporting international growth
May 15, 2025Medical Communications, Sales and Marketing Corporate, European Innovation Council (EIC), Immunology, Neogap Therapeutics, US pharma market, biotech, immunotherapy
Swedish biotech company, Neogap Therapeutics, has been selected to participate in the EIC Soft-landing Programme for Healthcare and Life Sciences …
Kaerus Bioscience secures FDA approval for rare genetic disorder treatment
May 15, 2025Research and Development FDA, Fragile X syndrome, Kaerus Bioscience, Orphan Drug Designation (ODD), Rare Diseases, Rare Pediatric Drug Designations (RPDD), genetic syndromes
Kaerus Bioscience announces that its lead candidate KER-0193 has been granted both Orphan Drug Designation (ODD) and Rare Pediatric Drug …
Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement
May 14, 2025Research and Development Corporate, Cure.Bio Portfolio Company, Pharmacy, Secarna Pharmaceuticals, agreement
Global biopharma company, Secarna Pharmaceuticals, and biotech investor, Cure.Bio, have announced signing a research and option agreement, intending to accelerate …
Tozaro forms Technical Advisory Board to accelerate Smart Polymer commercialisation for CGT bioprocessing
May 14, 2025Manufacturing and Production, Research and Development CGT production, Cell and Gene Therapy (CGT), Contraception, Pharmacy, Tozaro, advisory board
Tozaro, a UK-based biopharma focused on cell and gene therapy (CGT), has announced the formation of a Technical Advisory Board …
Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president
May 14, 2025Research and Development Corporate, Hansa Biopharma, Immunology, Pharmacy, biopharma, chief operating officer (COO), immunology
Swedish biopharma company Hansa Biopharma has appointed Maria Törnsén as chief operating officer (COO) and president US effective 19 May …
Donato Spota appointed as chief financial officer at Eleva
May 14, 2025Research and Development Eleva, Pharmacy, appointment, biopharma, chief financial officer (CFO)
German biopharma company, Eleva, has appointed Donato Spota as its new chief financial officer (CFO) and managing director to support …
Newron’s programme for treatment-resistant schizophrenia therapy approved
May 13, 2025Research and Development Newron, Psychiatry, clinical trials, psychiatry, schizophrenia
Newron Pharmaceuticals has announced the approval for its ENIGMA-TRS phase 3 development programme evaluating evenamide as an add-on therapy to …
Terumo’s plasma donation system adopted by Join Parachute to expand access to lifesaving therapies
May 13, 2025Biotech/start-up, Sales and Marketing Haematology, Join Parachute, Pharmacy, Terumo Blood and Cell Technologies (Terumo BCT), biotech, plasma donation
US Biotech company, Terumo Blood and Cell Technologies (Terumo BCT), has announced that Join Parachute will adopt its Rika Plasma …
Thermosome secures FDA Orphan Drug Designation for soft tissue sarcoma therapy
May 12, 2025Research and Development European Medicines Agency (EMA), FDA, Oncology, Thermosome
Thermosome has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its lead candidate, THE001, …
Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025
May 12, 2025Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide
Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …
Moderna expands use of AI-ready R&D platform
May 12, 2025Business Services, Research and Development, Technical Consultancy AI, Benchling, Corporate, Moderna, R&D, digital transformation
Moderna has expanded its partnership with Benchling, a cloud-based research platform, to support its broader research organisation. Previously used by …
European Commission approves Johnson & Johnson’s Crohn’s disease therapy
May 12, 2025Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation
The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …
Mind the gap: men’s health and the need for progress
May 12, 2025Advocacy Development, Medical Communications, Medical Education, Research and Development Androlabs, Men's Health Strategy, Men's mental health, Movember Foundation, Pharmacy, Psychiatry, mental health
From prostate cancer to hormonal health, many areas of men’s health require more attention. As male life expectancy and healthy …
